+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Oligodendroglioma Pipeline Analysis and Outlook, 2019

  • ID: 4772464
  • Report
  • 75 pages
  • VPA Research
until Dec 31st 2019
1 of 3


  • Bayer AG
  • CDG Therapeutics Inc
  • Eli Lilly and Co
  • Ipsen SA
  • Oblato Inc
  • Seattle Genetics Inc
  • MORE
Oligodendroglioma pipeline

Oligodendroglioma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Oligodendroglioma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Oligodendroglioma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Oligodendroglioma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Oligodendroglioma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Oligodendroglioma pipeline Profiled in detail

Key players actively participating in Oligodendroglioma pipeline are profiled along with their R&D progress in Oligodendroglioma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Oligodendroglioma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Oligodendroglioma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Oligodendroglioma pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Oligodendroglioma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Oligodendroglioma pipeline study
  • All recent news and developments related to Oligodendroglioma drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • Bayer AG
  • CDG Therapeutics Inc
  • Eli Lilly and Co
  • Ipsen SA
  • Oblato Inc
  • Seattle Genetics Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Oligodendroglioma Disease Overview

3. Oligodendroglioma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Oligodendroglioma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Oligodendroglioma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Oligodendroglioma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Oligodendroglioma Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Bayer AG
  • Bristol-Myers Squibb Co
  • CDG Therapeutics Inc
  • Cephalon Inc
  • Eli Lilly and Co
  • EpicentRx Inc
  • Immatics Biotechnologies GmbH
  • Ipsen SA
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Oblato Inc
  • Pfizer Inc
  • Seattle Genetics Inc
  • Taiho Pharmaceutical Co Ltd
  • Tocagen Inc
Note: Product cover images may vary from those shown